July 17, 2014 / Last updated : July 17, 2014 Benjamin Clark Pharmaceuticals Eli Lilly & Co. Quarterly Valuation – July 2014 $LLY Eli Lilly & Company is suitable for the Enterprising Investor but not the Defensive Investor. The Defensive Investor has concerns with the low current ratio, lack of stable earnings over the last ten years, and high PB ratio.
